Renal Cell Carcinoma

NASHVILLE, Tenn. — Nizar M. Tannir, MD, FACP, received the Nicholas J. Vogelzang Humanitarian Award from the Kidney Cancer Association.

NASHVILLE, Tenn. — Venous tumor thrombus appeared associated with elevated rates of pulmonary metastasis among patients with clear cell renal cell carcinoma, according to study results.

NASHVILLE, Tenn. — Diabetes appeared linked to shorter survival among patients who underwent nephrectomy for renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium: North America.

MADRID — In this video with Healio, Tian Zhang, MD, talked about “the bench-to-bedside journey of belzutifan” highlighted in the LITESPARK-005 study.

MADRID — In this video, Sumanta (Monty) Pal, MD, FASCO, shared his excitement about belzutifan data, a “big development” of ESMO Congress, in the renal cell carcinoma space.

Stereotactic ablative body radiotherapy conferred 100% disease control and cancer-specific survival over a 3-year follow-up period among older adults with inoperable kidney cancer, results from a phase 2 study showed.

The FDA announced several regulatory actions.

Belzutifan prolonged PFS compared with everolimus for certain patients with advanced renal cell carcinoma, according to topline data released by the agent’s manufacturer.

A presentation at ASCO Annual Meeting supported the use of first-line axitinib and pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

The FDA announced several regulatory actions the past few weeks.